GlassScriptPhysician profile
Delaura Patel
NPI 1023374675
$3,169.03
in general payments reported to CMS, 2019-2025
36 companies · $808 in 2025
The $808 reported for 2025 was more than what 88% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $62.89 · 2021: $224 · 2022: $568 · 2023: $670 · 2024: $680 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,145 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,145.11 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $520.14 | 2019-2023 | |
| Coopersurgical, INC. | $319.15 | 2019-2025 | Endosee, Ally II Ups, Paragard T 380a |
| Astellas Pharma US INC | $273.24 | 2023-2025 | Veozah |
| Pfizer INC. | $154.94 | 2021-2024 | |
| Exeltis, USA INC. | $154.74 | 2021-2025 | Slynd |
| Sumitomo Pharma America, INC. | $147.78 | 2023-2025 | Myfembree |
| Shield Therapeutics INC | $140.91 | 2023-2025 | Accrufer |
| Myovant Sciences INC. | $130.16 | 2021-2022 | |
| Intuitive Surgical, INC. | $124.48 | 2025 | |
| Biogen, INC. | $116.00 | 2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $105.37 | 2021-2025 | |
| Organon LLC | $101.35 | 2022-2024 | Nexplanon |
| Agile Therapeutics, INC. | $77.51 | 2023-2024 | Twirla |
| Janssen Biotech, INC. | $73.77 | 2022 | |
| Sage Therapeutics, LLC | $70.54 | 2025 | Zurzuvae |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $62.02 | 2024-2025 | |
| Millicent US INC | $59.88 | 2024 | Intrarosa |
| Merck Sharp & Dohme LLC | $55.74 | 2022-2024 | Gardasil 9, Gardasil |
| Meditrina | $50.77 | 2023-2025 | |
| Gynesonics, INC. | $48.18 | 2023-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Hologic Sales and Service, LLC | $47.38 | 2024-2025 | Acessa Provu System, Myosure Tissue Removal Device |
| Optumhealth Care Solutions, LLC | $47.30 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Mylan Pharmaceuticals INC. | $32.52 | 2020-2022 | |
| Ascend Therapeutics US, LLC | $32.00 | 2022-2024 | |
| Avion Pharmaceuticals | $25.85 | 2022-2023 | Balcoltra |
| Organogenesis INC. | $23.91 | 2024 | |
| Sanara Medtech INC. | $22.98 | 2025 | Celleraterx |
| Medtronic, INC. | $22.56 | 2023 | Truclear |
| Novo Nordisk INC | $20.17 | 2024 | |
| Supernus Pharmaceuticals, INC. | $19.19 | 2025 | Qelbree |
| Guard Medical INC. | $18.23 | 2025 | Npseal |
| Smith+Nephew, INC. | $14.93 | 2024 | Pico 14 |
| Alydia Health | $14.00 | 2021 | |
| Ethicon US, LLC | $13.92 | 2020 | |
| Minerva Surgical, INC | $13.78 | 2022 | |
| Therapeuticsmd, INC. | $13.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Delaura Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.